News | April 14, 2024
Briefs: Sun Pharma and Kimia Biosciences
Sun Pharma's Dadra facility receives OAI status from US FDA
Sun Pharma's Dadra facility receives OAI status from US FDA
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
10+ emerging markets, Japan & ANZ transition in final phase
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Yesafili, received marketing authorization approval from the European Commission for the European Union
Over 34 lakh children and 6 lakh pregnant women were administered vaccine doses during the first 2 rounds of IMI 5.0 campaign across the country
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)